Markus Heep Email & Phone Number

Freiburg Im Breisgau, BW, DE

Wuppertal, NRW, DE

Critical reviews or milestone activities: Discoveric Beta, Amplyx, Scynexis, Aelin, HIPS, Mutabilis, Utility, AM-Pharma, Allecra

Oslo, NO

Tübingen, Baden-Württemberg, DE

Working on mRNA vaccines

Geneva, Switzerland, CH

Supporting clinical development of Zoliflodacin, and new antibiotic candidates

The BL/BLI combination cefepime/AAI101 in Phase 3 clinical development reached superiority on primary endpoint.Piperacillin/AAI101 combination has completed Phase 1 clinical development

Manchester, England, GB

F2G is moving F901318, a novel IV/oral systemic antifungal into clinical trials.F901318 represents a novel class of antifungals and will be developed for treatment of invasive aspergillosis as well as for treatment of infections with other resistant moulds including Scedosporium prolificans.

Cincinnati, OH, US

Medical management and expertise for design and conduct of clinical trials, e.g. cUTI, VAP, cIAI, CDiff, including safety components, regulatory meetings, study reports, and manuscripts.Assisted in all phases of studies and trials including feasibility assessments, protocol design processes, educational efforts, management of medical information, and.

Basel, Baselstadt, CH

Phase III design of Omadacycline (new tetracycline antibiotic), Phase IV development of Cubicin (daptomycin medical affairs)

Allschwil, Basel-Country, CH

Ceftobiprole Phase II and III (skin and respiratory infections CAP HAP VAP)Isavuconazole Phase II and III design (esoph. candidiasis, inv. aspergillosis, zygomycosis, candidemia)Discovery and DD for antibiotics and systemic antifungals (Preclinical screening to Phase III).

Physician, Hematology Ward